Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
BUSINESS ACCOUNT
Sign up for a business account to:
-
Access reports individually or via Subscription
-
Receive monthly invoices with payment via CSA or hard dollars
Get access to other exclusive features
-
Analyst access
-
Free Trial Subscriptions
-
Team account with shared subscriptions
-
Advanced analytics to track research consumption and performance
Stifel Europe Limited Research
- Stifel Europe Limited Research
Discontinuing Coverage Ahead of Stifel Integration
On June 2, 2025, Stifel Financial Corporation acquired Bryan, Garnier & Co Limited and Bryan Garnier Securities, which have been rebranded to Stifel Europe Limited and Stifel Europe Securities, respectively. Today, August 22, 2025, both entities are being integrated into the Stifel research pla
Stifel Europe Limited Research
- Stifel Europe Limited Research
Mahaut Arnaud ... (+3)
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Alfen: H1 2025 results, mid-term outlook lowered
Alfen published H1 2025 figures yesterday. Revenue came in at EUR211.5m (-13.9% YoY vs. EUR245.7m in H1 2024) mainly with challenging dynamics in EV charging and Energy Storage, while benefiting from favourable base effects in Smart Grids, which was impacted by moistening issues in Q2 2024. This wa
Damien Choplain ... (+2)
- Damien Choplain
- Oscar Haffen Lamm
Egetis Q2: initial Germany launch, key catalysts still ahead
Egetis has reported Q2 results, marking the first commercial sales of Emcitate in Germany following its 1st May launch, and a cash position of SEK203m, providing an est. runway into Q1 2026. While exact German sales figures remain undisclosed, SEK14.5m in total revenues (vs SEK13.9m in Q2 2024) inc
Oscar Haffen Lamm
- Oscar Haffen Lamm
Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initia...
Cinclus’ Q2 update focused on balance sheet items and a recap of corporate achievements. The company reported a cash position of SEK589m and operating expenses of SEK80.9m, up from the prior quarter - consistent with expectations given the Phase 3 trial ramp-up. With support from the Zentiva partne
Gregory Ramirez
- Gregory Ramirez
Thibault Morel
- Thibault Morel
Cedric Rossi
- Cedric Rossi
HUGO BOSS: Successful execution and healthy geo mix lead to raised FY2...
HUGO BOSS - NEUTRAL | EUR68 vs. EUR64 Successful execution and healthy geo mix lead to raised FY22 guidance Strong sales and EBIT beat in Q2 driven by execution… … and low exposure to China’s lockdowns FY22 sales and EBIT guidance revised upwards and we increase our FY22-23 estimates by 7%
Clement Genelot
- Clement Genelot